Abstract:Purpose/Objective(s) According to NCCN guidelines, concurrent chemoradiation (CCRT) is the standard care for locally advanced cervical cancer (LACC) patients, but the benefit of neoadjuvant chemotherapy (NACT) before CCRT for LACC patients is still controversial, especially based on 2018FIGO staging,This study is designed to answer the question by comparing the efficacy and toxicities of neoadjuvant chemotherapy with concurrent chemoradiation (NACT+CCRT) versus concurrent chemoradiation (CCRT) alone in LACC under 2018FIGO staging correction. Materials/Methods Patients with stage IB2, IIA2, IIB-IVA (2009 FIGO staging) cervical cancer were retrospectively reviewed from January 2013 to January 2017 in China. All patients were re-staged after 2018FIGO staging correction. All patients were treated with IMRT to 50.4 Gy with concurrent weekly cisplatin 40 mg/m2 followed by intra-cavitary brachytherapy. The primary endpoint was progression free survival (PFS), and the secondary endpoints included overall survival (OS), tumor response by RECIST 1.1 criteria, and toxicities. Survivals were calculated with Kaplan-Meier method. The differences between survivals were calculated with Log-rank test. Toxicities were analyzed using the χ2 test. All statistical tests were two-sided. Results A total of 432 patients were identified and 406 were eligible for analysis. The 2009FIGO staging of IB2 in 81, stage IA2 and IIB in 119, stage III in 119, stage IV in 87 were corrected into 2018FIGO staging which IB3 in 58, stage IIA2 and IIB in 75, stage III in 186, and stage IV in 87. No patients were down-staged. 201 patients were treated with NACT+CCRT and 205 with CCRT. With a median follow-up of 58.6 months, 5-year PFS was 60.3% in the NACT+CCRT arm, and was 57.6% in the CCRT arm. There was no significant difference in 5-year PFS between two arms (p=0.287). 5-year OS was 68.8% and 65.0% in the NACT+CCRT arm and CCRT+ACT arm, respectively. There was no statistical difference in 5-year OS between two arms (p=0.301). Multivariate analysis showed that pathological type, FIGO stage and pelvic nodes status were associated with OS and PFS. The CR and PR in NACT group was similar to the CCRT group (196/201 versus 193/205, p=0.090). There were higher acute systemic side effects in the NACT+CCRT arm. The result of subgroup analysis showed that PFS in stage III in NACT+CCRT group was significantly higher than that in CCRT group (57.6% vs 45.4%, P=0.048), but OS had no significant difference (71.9% vs 56.3%, P=0.053). In stage III, the curative effect of IIIC1 was better than that of IIIA-B and IIIC2, with 5-year OS of 81.9%, 61.7% and 37.5% (P=0.004), and 5-year PFS of 62.6%, 48.8% and 38.4% (P=0.031), respectively. Conclusion For LACC patients with 2018 FIGO correction stage, neoadjuvant chemotherapy plus concurrent cisplatin chemoradiation did not improves RR, PFS and OS. There were more toxicities for the neoadjuvant chemotherapy group. Further research and longer follow up is needed, especially for the staging IIIC1 LACC patients.

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer

Clinical efficacy and safety of neoadjuvant chemotherapy with paclitaxel and cisplatin in combination with concurrent chemoradiotherapy for locally advanced cervical cancer: a systematic review and meta-analysis

The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.

Paclitaxel Plus Platinum Neoadjuvant Chemotherapy Followed by Surgery Versus Primary Surgery in Locally Advanced Cervical Cancer—A Propensity Score Matching Analysis

Neoadjuvant Chemotherapy with Weekly Cisplatin and Paclitaxel Followed by Chemoradiation for Locally Advanced Cervical Cancer

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.

Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer

Neoadjuvant chemotherapy does not improve the prognosis and lymph node metastasis rate of locally advanced cervical squamous cell carcinoma: A retrospective cohort study in China.

Tumor-infiltrating CD8+ and FOXP3+ Lymphocytes Before and after Neoadjuvant Chemotherapy in Cervical Cancer

Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience.

Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Reduces Surgical Risks and Lymph-Vascular Space Involvement

Effectiveness of neoadjuvant chemotherapy followed by radical surgery in young patients with locally advanced cervical cancer

Acquired Treatment Response from Neoadjuvant Chemotherapy Predicts a Favorable Prognosis for Local Advanced Cervical Cancer

Comparison of Outcomes and Side Effects for Neoadjuvant Chemotherapy with Weekly Cisplatin and Paclitaxel Followed by Chemoradiation Vs. Chemoradiation Alone in Stage IIB–IVA Cervical Cancer: Study Protocol for a Randomized Controlled Trial

Survival outcomes of neoadjuvant chemotherapy-related strategies compared with concurrent chemoradiotherapy for locally advanced cervical cancer: a meta-analysis of randomized controlled trials

Therapeutic effect of neoadjuvant chemotherapy on local advanced cervical carcinoma

Comparison of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy Vs. Concurrent Chemoradiotherapy Alone in Locally Advanced Cervical Cancer under 2018FIGO Staging Correction

Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis

Premilinary Survival Results and Potential Beneficiaries for Locally Advanced Nasopharyngeal Carcinoma Treated with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy.

Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis.

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial